{"id":140922,"date":"2023-02-10T07:27:10","date_gmt":"2023-02-10T12:27:10","guid":{"rendered":"https:\/\/44.250.171.167\/?p=140922"},"modified":"2023-02-10T07:27:14","modified_gmt":"2023-02-10T12:27:14","slug":"alkem-laboratories-ltd-nse-alkem-q3-fy23-results-out-total-income-rises-15-yoy","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/alkem-laboratories-ltd-nse-alkem-q3-fy23-results-out-total-income-rises-15-yoy\/","title":{"rendered":"Alkem Laboratories Ltd. (NSE: ALKEM): Q3 FY23 Results Out; Total Income Rises 15% YoY"},"content":{"rendered":"\n

Alkem Laboratories Ltd.(NSE:ALKEM)<\/a> is a pharmaceutical company that specializes in developing, manufacturing, and marketing of pharmaceutical and nutraceutical products. The company operates in both the domestic and international markets. It offers a wide range of products in various therapeutic segments such as cardiology, gastroenterology, neurology, orthopedics, and more.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Alkem Laboratories Limited is an Indian pharmaceutical company with a focus on both domestic and international sales. During the 3rd quarter of the financial year 23 (Q3FY23), the company recorded a total revenue of Rs. 30,409 million with a YoY growth of 16.1%. India sales accounted for Rs. 19,922 million, a growth of 9.7%, while international sales were Rs. 9,928 million, a growth of 28.8%. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) was Rs. 5,990 million, resulting in an EBITDA margin of 19.7%. R&D expenses for the quarter were 4.3% of total revenue from operations. The Profit Before Tax (PBT) was Rs. 5,389 million, a growth of 16.2% compared to Q3FY22, while the Net Profit was Rs. 4,547 million, a YoY decline of 13.5%.<\/p>\n\n\n\n

For the 9 months period ending December 31, 2022 (9MFY23), the company recorded total revenue from operations of Rs. 86,967 million with a YoY growth of 6.7%. India sales were Rs. 59,898 million, a YoY growth of 5.3%, while international sales were Rs. 25,823 million, a YoY growth of 9.1%. The EBITDA was Rs. 12,562 million, resulting in an EBITDA margin of 14.4%. The company’s R&D expenses for 9MFY23 were 4.5% of total revenue from operations. The Profit Before Tax (PBT) was Rs. 10,931 million, a decline of 31.7% compared to 9MFY22, while the Net Profit was Rs. 9,132 million, a YoY decline of 40.6%.<\/p>\n\n\n\n

In conclusion, Alkem Laboratories reported a strong growth in Q3FY23, with a good performance from both domestic and international sales. The company’s EBITDA margin and R&D expenses were in line with expectations. The company also generated healthy cash flows and strengthened its balance sheet with a strong net cash position. The recent development of Alkem’s biosimilar franchise, Enzene Biosciences, further instills confidence in the company’s future growth.<\/p>\n","protected":false},"excerpt":{"rendered":"

Alkem Laboratories Ltd.(NSE:ALKEM) is a pharmaceutical company that specializes in developing, manufacturing, and marketing of pharmaceutical and nutraceutical products. The company operates in both the domestic and international markets. It offers a wide range of products in various therapeutic segments such as cardiology, gastroenterology, neurology, orthopedics, and more. Alkem Laboratories Limited is an Indian pharmaceutical […]<\/p>\n","protected":false},"author":1932,"featured_media":140924,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392,5747],"tags":[1115],"class_list":["post-140922","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","category-healthcare-stocks","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/bb3df30c-f366-48d9-a0f1-d7a6be8c4ba8.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":170582,"url":"https:\/\/alphastreet.com\/india\/alkem-laboratories-q1-fy26-earnings-results\/","url_meta":{"origin":140922,"position":0},"title":"Alkem Laboratories Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 25, 2025","format":false,"excerpt":"Alkem Laboratories Ltd is a global pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b93,371 crore, up 11.18% year-on-year (YoY) from \u20b93,032 crore in Q1 FY25. Total Expenses: \u20b92,750 crore, up 8.61%\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"ALKEM Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":180788,"url":"https:\/\/alphastreet.com\/india\/alkem-laboratories-posts-11-revenue-growth-in-q3-fy26-amid-strategic-medtech-push\/","url_meta":{"origin":140922,"position":1},"title":"Alkem Laboratories Posts 11% Revenue Growth in Q3 FY26 Amid Strategic MedTech Push","author":"Staff Correspondent","date":"February 13, 2026","format":false,"excerpt":"Alkem Laboratories Ltd. (NSE: ALKEM), a major Indian pharmaceutical player, reported solid unaudited financial results for the third quarter ended December 31, 2025. Total revenue from operations grew 10.7% year-over-year (YoY) to Rs. 37,368 million, driven by robust international expansion. The company also unveiled a binding term sheet for acquiring\u2026","rel":"","context":"In "Analysis"","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":142492,"url":"https:\/\/alphastreet.com\/india\/earnings-alkem-laboratories-ltd-nsealkem-q3fy23-results-out-total-income-rise-15-yoy\/","url_meta":{"origin":140922,"position":2},"title":"Earnings | Alkem Laboratories Ltd.(NSE:ALKEM): Q3FY23 Results Out; Total Income rise 15% YoY","author":"Divyansh_Kasana","date":"February 22, 2023","format":false,"excerpt":"Alkem Laboratories Ltd.(NSE:ALKEM) is a pharmaceutical company based in India that specializes in the manufacturing and marketing of generic and branded drugs, including formulations, active pharmaceutical ingredients (APIs), and nutraceuticals. The company was founded in 1973 and has since grown into one of the top pharmaceutical companies in India, with\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":154532,"url":"https:\/\/alphastreet.com\/india\/alkem-laboratories-good-times-ahead\/","url_meta":{"origin":140922,"position":3},"title":"Alkem Laboratories: Good times ahead?","author":"Karan_Singh","date":"September 5, 2023","format":false,"excerpt":"\u201cThis growth was primarily fueled by strong performance of our business in international markets wherein we have crossed Rs.1000 Crores for the quarter for the first time. Several key factors including the softening of select raw material prices, a favourable currency impact, easing of freight costs and the successful implementation\u2026","rel":"","context":"In "Health Care"","block_context":{"text":"Health Care","link":"https:\/\/alphastreet.com\/india\/category\/healthcare-stocks\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/iStock-1345489729.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/iStock-1345489729.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/iStock-1345489729.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/iStock-1345489729.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":172398,"url":"https:\/\/alphastreet.com\/india\/alkem-laboratories-q2-fy26-earnings-results\/","url_meta":{"origin":140922,"position":4},"title":"Alkem Laboratories Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"November 14, 2025","format":false,"excerpt":"Alkem Laboratories, engaged in the pharmaceutical and nutraceutical business with global operations, reported steady financial results for Q2FY26. Financial Highlights: Revenues increased 17.16% year-on-year to \u20b94,001 crore from \u20b93,415 crore. Total expenses rose 15.89% to \u20b93,209 crore from \u20b92,769 crore. Consolidated net profit grew 10.97% to \u20b9779 crore from \u20b9702\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/A-3.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/A-3.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/A-3.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/A-3.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/A-3.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/A-3.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":165768,"url":"https:\/\/alphastreet.com\/india\/alkem-laboratories-ltd-q2fy25-14-rise-in-profits\/","url_meta":{"origin":140922,"position":5},"title":"Alkem Laboratories Ltd Q2FY25; 14% rise in Profits","author":"Divyansh_Kasana","date":"November 21, 2024","format":false,"excerpt":"Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107) Financial Results: Alkem Laboratories Ltd reported Revenues for Q2FY25 of \u20b93,415.00 Crores down from \u20b93,440.00 Crore year on year,\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/11\/FG.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/11\/FG.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/11\/FG.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/11\/FG.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/11\/FG.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/11\/FG.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/140922","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=140922"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/140922\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/140924"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=140922"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=140922"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=140922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}